A body of preclinical and correlative data suggests that selective inhibition of BRAF may have a number of immunomodulatory effects, including in enhanced T cell recognition and melanoma antigen expression, as well as increased T cell infiltration in the tumor supporting a rationale for combined therapy [89,90,91]. Here, BRAF is linked to melanoma.